IBAI

Imaging Biometrics Limited

Health Care First-pass screen £1.42m

360/1000 Overall fit

AI beneficiary 35% 42

Operating leverage 25% 35

Valuation 25% 30

Downside protection 15% 35

First-pass take

Early-stage medical imaging software company with AI technology components in strategy (IB Zero G, automated segmentation) but minimal revenue from AI products yet. Core medical software segment is profitable (£47k), but consolidated losses of £501k driven by holding-company costs and new Oral GaM pharma R&D (£169k). Revenue flat at £536k; cash declining rapidly (£415k burn in 2022). Dependent on future fundraising.

Flags

loss-makingno-valuation-dataearly-stagecash-dependentclinical-trial-stagenegative-working-capital